CALADRIUS BIOSCIENCES INC (CLBS)
Caladrius Biosciences Inc. a clinical-stage biopharmaceutical company develops cell based therapeutics in the United States. It is developing NBS20 a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma NBS10 a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction and NBS03D an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes.
USD
2,45
| Fecha/Hora: 04/08/2020 | Volumen: 514.262 |
| Mínimo: 2,25 | Últ. cierre: 2,35 |
| Máximo: 2,55 | Apertura 2,34 |
-
Vender
-
Comprar
Datos Intradiarios
| Hora | Precio | Volumen |
|---|
NASDAQ
Datos técnicos
| P/E: | EBITDA(MM): |
| Beta: | Ventas: |
| Capitalización(MM): | P/Ventas: |
| P/BV: | ROE(%): |
| Rtado. Neto(MM): |
Gráficos por TradingView
Fuente: Reuters. Las cotizaciones tienen una demora de al menos 20 minutos. - Información diferida en 30 minutos - Prohibida su reproducción total o parcial